Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Infectech, Inc. Awarded Attorney Fees and Costs After Federal Court Dismissed Involuntary Petition
February 24, 2003

Infectech, Inc. has received notification of an order granting fees and costs which the company incurred in obtaining a dismissal of an involuntary petition which had been brought by three insiders. The U.S. Bankruptcy Court for the Western District of Pennsylvania entered a judgment of $18,500 jointly and severally against the petitioners Paul Tanner, Carl Shardy and Robert A. Ollar. Infectech management contended that this was a bad faith filing with the sole intent of private gain by the insiders, and the company believes that this ruling further corroborates that contention.

Infectech, Inc., a biotechnology/genomics company, became a publicly traded company in April 1999. The company specializes in the research, development and production of laboratory kits used in the rapid identification and antibiotic testing of disease-causing pathogens. The company's patents span the identification and antibiotic sensitivity testing of 34 disease- causing bacteria, including Tuberculosis, Pseudomonas, M. avium and Nocardia. These bacteria are cited as a prominent cause of death in patients with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing surgery. Infectech, Inc. is majority-owned by Nutra Pharma Corp. (OTC Bulletin Board: NPHC - News)

The company's web site is www.infectech.com.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The award of attorney fees and costs to Infectech should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


May 31, 2017
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics